Stockscreener 앱 받기
3.915
1.16%
0.045
시간 외 거래:
3.95
0.035
+0.89%
전일 마감가:
$3.87
열려 있는:
$3.85
하루 거래량:
882.22K
Relative Volume:
1.55
시가총액:
$1.22B
수익:
$563.46M
순이익/손실:
$27.92M
주가수익비율:
40.61
EPS:
0.0964
순현금흐름:
$-146.33M
1주 성능:
-5.43%
1개월 성능:
+18.28%
6개월 성능:
-21.70%
1년 성능:
-57.54%
1일 변동 폭
$3.75
$4.09
1주일 범위
$3.75
$4.45
52주 변동 폭
$2.94
$9.94
Alvotech Stock (ALVO) Company Profile
Compare ALVO vs TAK, HLN, TEVA, ZTS, UTHR
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ALVO
Alvotech
|
3.915 | 1.32B | 563.46M | 27.92M | -146.33M | 0.0964 |
TAK
Takeda Pharmaceutical Co Adr
|
15.42 | 49.83B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
8.87 | 40.04B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
32.56 | 39.23B | 17.53B | 1.58B | 444.18M | 1.3457 |
ZTS
Zoetis Inc
|
77.26 | 33.52B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
551.47 | 23.33B | 3.17B | 1.29B | 1.01B | 27.09 |
Alvotech Stock (ALVO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-12-09 | 개시 | Barclays | Underweight |
| 2025-11-04 | 다운그레이드 | Deutsche Bank | Buy → Hold |
| 2025-10-14 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2025-09-23 | 업그레이드 | Deutsche Bank | Hold → Buy |
| 2025-02-14 | 개시 | UBS | Buy |
| 2024-01-29 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2023-10-20 | 업그레이드 | Citigroup | Sell → Neutral |
| 2023-09-21 | 개시 | Barclays | Equal Weight |
| 2022-09-07 | 개시 | Morgan Stanley | Equal-Weight |
| 2022-09-06 | 다운그레이드 | Citigroup | Buy → Sell |
| 2022-07-26 | 개시 | Citigroup | Buy |
모두보기
Alvotech 주식(ALVO)의 최신 뉴스
Alvotech raises $152 million via two issues - Biostock
Alvotech prices $152M share offering and private placement to fund biosimilar development - Pluang
Alvotech Prices Public Offering of 22.7 Million Ordinary Shares at $3.75 per Share - Quiver Quantitative
Alvotech Prices Offering Of 22.67 Million Ordinary Shares At $3.75 Per Share - TradingView
Alvotech's $125M Gamble: Fueling a Biosimilar Pipeline Amidst Headwinds - BriefGlance
Jefferies (JEF) Involved in Alvotech's Share Issuance Suspension - GuruFocus
ALVO SEC FilingsAlvotech 10-K, 10-Q, 8-K Forms - Stock Titan
Alvotech (ALVO) launches shelf offering; concurrent EEA private placement indicated - Stock Titan
Alvotech initiates $125M fundraising via public and private offering for biosimilar growth - MSN
12 Health Care Stocks Moving In Monday's After-Market SessionAlvotech (NASDAQ:ALVO), Anixa Biosciences - Benzinga
Alvotech Announces Proposed $125 Million Public Offering and Concurrent Private Placement of Ordinary Shares - The Manila Times
Alvotech (ALVO) terminates Jefferies ATM share prospectus - Stock Titan
Alvotech seeks $125M to fund biosimilar medicines via share sale - Stock Titan
Alvotech Stock (LU2557688560): Nordic-listed biosimilar player draws focus after latest trading move - AD HOC NEWS
Alvotech seeks FDA nod for Simponi, Eylea biosimilars again - Drug Store News
Alvotech announced that it expects to receive $66.849998 million in funding - marketscreener.com
Why Alvotech (ALVO) Is Up 17.8% After FDA Advances Its Entyvio Biosimilar AVT16 Application - simplywall.st
Alvotech hits critical inflection as biosimilar pipeline nears FDA decisions - MSN
Teva's Biosimilar Boom Is Just Getting Started. Is It Time to Buy This Rebounding Pharma Stock? - The Motley Fool
Alvotech shares jump after FDA accepts Entyvio biosimilar application for review (ALVO) - MSN
Alvotech gains on FDA acceptance of Entyvio biosimilar BLA - MSN
Alvotech allocates shares to a board director as part of his pay package, filed with Luxembourg regulator. - Pluang
Transactions of Managers and Closely Associated Persons - Stock Titan
Alvotech Hits Critical Inflection as Biosimilar Pipeline Nears FDA Decisions - MarketBeat
Transcript : Alvotech Presents at UBS Virtual Generics and Biosimilars Day, Jun-10-2026 10 - marketscreener.com
Alvotech seeks US nod for biosimilars to J&J’s Simponi and Regeneron’s Eylea again - MSN
ALVO: Poised for rapid biosimilar expansion, targeting key launches and market leadership by 2027 - TradingView
Alvotech (ALVO) Returns To Quarterly Profitability Challenging Concern Over Persistent Losses - simplywall.st
Alvotech resubmits BLA for proposed Eylea biosimilar - Eyes On Eyecare
Alvotech Takes The Lead On Vedolizumab - Citeline News & Insights
Assessing Alvotech (ALVO) Valuation After FDA Acceptance Of AVT16 Biosimilar Application - simplywall.st
Top Biotech Gainers: TNGX Hits New High, ALVO Moves Closer To FDA Approval, ZVRA, IDYA Turn Heads - RTTNews
Alvotech (ALVO) Secures FDA Review for New Biosimilar AVT16 - GuruFocus
Alvotech (NASDAQ: ALVO) Q1 2026 results and FDA review of key biosimilars - Stock Titan
FDA to review biosimilar of Entyvio - Managed Healthcare Executive
Alvotech (ALVO) Goldman Sachs 47th Annual Global Healthcare Conference 2026 summary - Quartr
Biggest stock movers Monday: NRIX, INTC, and more (NASDAQ:NRIX) - Seeking Alpha
ALVO: Accelerated U.S. biosimilar launches and global expansion drive strong growth outlook - TradingView
symbol__ Stock Quote Price and Forecast - CNN
Alvotech announces FDA acceptance of BLA for AVT16 biosimilar - grafa.com
Alvotech: Speculative 'Buy' Despite The FDA's CMC Requirements (NASDAQ:ALVO) - Seeking Alpha
US FDA Accepts Alvotech's Biologics License Application for Entyvio Biosimilar - Moomoo
Alvotech stock surges on FDA review of Entyvio biosimilar By Investing.com - Investing.com Canada
Why is Alvotech stock rallying today? - Investing.com UK
FDA accepts Alvotech's application for AVT16, a... | Pluang – Crypto, Stocks, Gold & Funds - Pluang
Alvotech stock surges on FDA review of Entyvio biosimilar - Investing.com
Alvotech (ALVO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.95%
1.13%
자본화:
|
볼륨(24시간):